BREAKING🔔 Here I want to quickly report our new results from G2P-Japan🇯🇵 before the preprint publication. We have elucidated the virological characteristics of SARS-CoV-2 KP.3.1.1 - a progeny of JN.1. Please RT🔥 1/
Cf.1 A new one, KP.2 (JN.1.11.1.2), has been already elucidated. 2/
Here we focused on a new one, KP.3.1.1 (JN.1.11.1.3.1.1). This variant harbors these mutations.
KP.3.1.1 spike = KP.3 spike + S31del. 4/
Transmissibility/fitness (Re): molecular phylogenetic-epidemic dynamics modeling led by Jumpei @jampei2 and Kaho showed that the Re of KP.3.1.1 is greater than those of the other JN.1 subvariants. 5/
Pseudovirus infectivity: KP.3.1.1 is more infectious than KP.3. 6/
Immune resistance: the 50% neutralization values of breakthrough infection (BTI) sera with XBB.1.5, EG.5.1, HK.3 and JN.1 as well as XBB.1.5 vaccine sera against KP.3.1.1 were significantly lower than those against KP.3 and even KP.2.3 in some cases🔥 7/
These results suggest that KP.3.1.1 has the potential to be predominant, due to its higher infectivity and increased immune evasion. In particular, #S31del in spike, the common mutation in KP.3.1.1, LB.1 and KP.2.3, is likely to be a key mutation. 8/8
• • •
Missing some Tweet in this thread? You can try to
force a refresh
BREAKING🔔 Here I want to quickly report our new results from G2P-Japan🇯🇵 before the preprint publication. We have elucidated the virological characteristics of SARS-CoV-2 KP.3, LB.1 and KP.2.3 - progeny of JN.1. Please RT🔥 1/
Cf. A new one, KP.2 (JN.1.11.1.2), has been already elucidated. 2/
BREAKING🔔 A new study from G2P-Japan🇯🇵 is out at bioRxiv @biorxivpreprint. We elucidated the virological characteristics of SARS-CoV-2 KP.2 - a progeny of JN.1. Please RT🔥 1/ biorxiv.org/cgi/content/sh…
Cf. This is KP.2 (aka JN.1.11.1.2). In spike, KP.2 = JN.1 + S:R346T, S:F456L & S:V1104L).
We remember that R346T was observed in BQ.1.1 and XBB lineages, while F456L is a hallmark of EG.5 lineage. 2/
Transmissibility/fitness (Re): molecular phylogenetic-epidemic dynamics modeling led by Jumpei @jampei2 and Kaho showed that the Re of KP.2 is ~1.2-fold greater than that of JN.1. 3/
BREAKING🔔 The 32nd paper from G2P-Japan🇯🇵 is out at Lancet Infectious Diseases @TheLancetInfDis. We show the breadth of antisera induced by XBB.1.5 monovalent vaccine - comparison between infection-naïve and XBB-infected individuals. Please repost🔥 1/ thelancet.com/journals/lanin…
To control SARS-CoV-2 infection, the XBB.1.5 monovalent vaccine is now available. However, we found that natural infection with XBB subvariants, including XBB.1.5, does not efficiently induce humoral immunity against the infecting XBB subvariants, e.g. 2/
These observations raise the possibility that the XBB.1.5 monovalent vaccine may not be able to efficiently induce humoral immunity against emerging SARS-CoV-2 variants, including a variety of XBB subvariants as well as BA.2.86 and JN.1. 3/